Supplementary file 3_Efficacy and safety of immune checkpoint inhibitors combined with ant

A systematic review and meta-analysis published in 2026, aggregating data from 11 clinical trials involving 1,491 patients with advanced cervical cancer. The work, authored by Dezhi Zhang, evaluates the efficacy and safety of combining immune checkpoint inhibitors with antiangiogenic agents. It includes three randomized controlled trials and eight single-arm studies.

Use Cases

• Compare overall survival (OS) and progression-free survival (PFS) outcomes between combination therapy and control groups based on hazard ratios.
• Assess the objective response rate (ORR) and disease control rate (DCR) reported across multiple trials.
• Evaluate the safety profile and incidence of adverse events (AEs), including severe toxicity rates.
• Validate the robustness of meta-analysis findings through sensitivity analyses based on heterogeneity metrics.

Strengths

• Aggregates data from 11 clinical trials encompassing 1,491 patients, providing a substantial sample size.
• Includes three randomized controlled trials (RCTs) for first-line treatment, offering higher evidence quality.
• Reports specific statistical outcomes, including a 16% reduction in death risk (HR=0.84) and an 18% reduction in progression risk (HR=0.82).

Limitations

• The dataset is a 467.4 KB DOCX file, suggesting limited raw data and a focus on textual analysis results.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect publication bias inherent to systematic reviews of published clinical trials.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of studies from PubMed, Embase, Cochrane Library, Web of Science, and Scopus.

Freshness

Last updated 2026-05-21 05:34:05.